| Rev. Neurol.
| [0059]
|
| Nature Reviews Neurology
| [0059]
|
| Neural Transm. Suppl.
| [0059]
|
| Nat. Rev. Drug Discov.
| [0059]
|
| Science
| [0060]
|
| Proc. Natl. Acad. Sci. U S A.
| [0060]
|
| J. Neurochem.
| [0060]
[0294]
|
| J Neurochem
| [0060]
[0294]
|
| J. Neurosci.
| [0060]
|
| Proc. Natl. Acad. Sci. U S A.
| [0060]
|
| Neurobiol. Aging
| [0060]
|
| Nat. Genet.
| [0060]
|
| Neurosci. Lett.
| [0060]
|
| Genes Dev.
| [0061]
[0061]
[0061]
|
| Biochim. Biophys. Acta
| [0061]
|
| Science
| [0061]
[0061]
|
| ACS Chem. Neurosci.
| [0061]
[0061]
[0071]
|
| Science
| [0061]
|
| J. Neurosci.
| [0061]
|
| Mov. Disord.
| [0069]
|
| CNS Drugs
| [0069]
|
| Neurotherapeutics
| [0069]
|
| Curr. Top. Med. Chem.
| [0072]
|
| Expert Opin. Drug Discov.
| [0074]
|
| Remington: The Science and Practice of Pharmacy
| [0080]
|
| The United States Pharmacopeia: The National Formulary
| [0080]
|
| Neurology
| [0088]
|
| J. Org. Chem.
| [0090]
|
| Chem. Pharm. Bull.
| [0090]
|
| Bioorg. Med. Chem.
| [0090]
|
| J. Med. Chem.
| [0099]
|
| Nucl. Med. Biol.
| [0099]
|
| Protective Groups in Organic Synthesis
| [0099]
|
| J. Fluorine Chem.
| [0105]
[0120]
|
| Khim. Geterotsikl.
| [0115]
|
| J. Org. Chem.
| [0115]
|
| Org. Lett.
| [0126]
|
| Org. Prep. Procedure Int.
| [0126]
|
| Bull. Chem. Soc. Jpn.
| [0126]
[0128]
[0132]
|
| Org. Biomol. Chem.
| [0130]
[0132]
|
| J. Org. Chem.
| [0134]
|
| J. Org. Chem.
| [0150]
|
| Synthesis
| [0150]
|
| Chem. Pharm. Bull.
| [0168]
|
| Nucl. Med. Biol.
| [0172]
|
| Mol Neurobiol.
| [0292]
|
| J. Neurosci.
| [0295]
[0296]
[0302]
|
| Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease
| [0305]
|
| Expression of retinoic acid receptors and retinoid X receptors in normal and vitamin A deficient adult rat brain
| [0306]
[0343]
|
| selective group of dopaminergic neurons express Nurr1 in the adult mouse brain
| [0307]
|
| The Psychopathology of Affectivity: Conceptual and Historical Aspects
| [0308]
|
| NURR1 mutations in cases of schizophrenia and manic-depressive disorder
| [0309]
|
| Psychology the science of behavior
| [0310]
|
| Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
| [0311]
|
| Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra
| [0312]
|
| Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
| [0313]
|
| A study of the role of serotonin in the anxiolytic effect of nitrous oxide in rodents
| [0314]
|
| The Mouse Brain in Stereotaxic Coordinates
| [0315]
[0346]
|
| Translated mutation in the Nurr1 gene as a cause for Parkinson's disease
| [0316]
|
| Disease modification in Parkinson's disease
| [0317]
[0347]
|
| Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson disease
| [0318]
|
| NR4A2 genetic variation in sporadic Parkinson's disease: a genewide approach
| [0319]
|
| Neuropilin1 is a direct downstream target of Nurr1 in the developing brain stem
| [0320]
|
| Effects of a unilateral stereotaxic injection of Tinuvin 123 into the substantia nigra on the nigrostriatal dopaminergic pathway in the rat
| [0321]
|
| A Nurr1 point mutant, implicated in Parkinson's disease, uncouples ERK1/2-dependent regulation of tyrosine hydroxylase transcription
| [0322]
|
| Mutations in NR4A2 associated with familial Parkinson disease
| [0323]
|
| Melancholia: A Historical Review.
| [0324]
|
| Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice
| [0325]
|
| VIP is a transcriptional target of Nurr1 in dopaminergic cells
| [0326]
|
| Animal models of the non-motor features of Parkinson's disease
| [0327]
|
| Vigilance states in a parkinsonian model, the MPTP mouse
| [0328]
|
| Novel method for high-throughput phenotyping of sleep in mice
| [0329]
|
| I-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment
| [0330]
|
| Acute and long term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in tests of nociception in mice
| [0331]
|
| Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine
| [0332]
|
| Characterisation of a novel NR4A2 mutation in Parkinson's disease brain
| [0333]
|
| Microarray analyses support a role for Nurr1 in resistance to oxidative stress and neuronal differentiation in neural stem cells
| [0334]
|
| Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease
| [0335]
|
| Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders
| [0336]
|
| Alpha-synuclein upregulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP
| [0337]
|
| Bdnf gene is a downstream target of Nurr1 transcription factor in rat midbrain neurons in vitro
| [0338]
|
| Nurr1-RXR heterodimers mediate RXR ligandinduced signaling in neuronal cells
| [0339]
[0353]
|
| Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors
| [0340]
[0354]
|
| Distribution of messenger RNAs for the orphan nuclear receptors Nurr1 and Nur77 in adult rat brain using in situ hybridization
| [0341]
|
| Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 in the dopaminergic system
| [0342]
|
| A selective group of dopaminergic neurons express Nurr1 in the adult mouse brain
| [0344]
|
| NURR1 in Parkinson disease--from pathogenesis to therapeutic potential
| [0345]
|
| How many drug targets are there?
| [0348]
|
| Modulation of RXR function through ligand design
| [0349]
|
| Acute and long term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in tests of nociception in mice
| [0350]
|
| Advances in drug design with RXR modulators
| [0351]
|
| Alpha-synuclein upregulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP
| [0352]
|